Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
- Revenue in JPY (TTM)3.20tn
- Net income in JPY180.63bn
- Incorporated1925
- Employees47.50k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Mergers & acquisitions
| Acquired company | 4502:TYO since announced | Transaction value |
|---|---|---|
| Nihon Pharmaceutical Co Ltd | 2.36% | 51.04m |
Data delayed at least 20 minutes, as of Mar 03 2021 00:05 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas Pharma Inc | 1.25tn | 138.31bn | 3.18tn | 15.88k | 22.99 | 2.32 | 15.13 | 2.54 | 74.41 | 74.41 | 674.20 | 736.79 | 0.5847 | 1.59 | 3.52 | 78,902,980.00 | 6.45 | 10.56 | 8.69 | 14.05 | 80.62 | 76.95 | 11.04 | 15.09 | 1.11 | -- | 0.2211 | 36.12 | -0.4214 | 0.8448 | -12.08 | 7.54 | -0.8211 | 5.92 |
| Alexion Pharmaceuticals, Inc. | 648.02bn | 64.42bn | 3.57tn | 3.84k | 56.41 | 2.86 | 35.82 | 5.50 | 2.69 | 2.69 | 27.40 | 53.08 | 0.3406 | 0.7889 | 4.58 | 1,581,939.00 | 3.39 | 5.30 | 3.68 | 5.71 | 90.88 | 90.68 | 9.94 | 17.95 | 3.11 | 46.65 | 0.1803 | 0.00 | 21.61 | 18.44 | -74.90 | 33.11 | -17.92 | -- |
| Takeda Pharmaceutical Co Ltd | 3.20tn | 180.63bn | 5.70tn | 47.50k | 31.43 | 1.22 | 7.63 | 1.78 | 114.96 | 114.96 | 2,035.14 | 2,965.00 | 0.2527 | 1.28 | 3.97 | 67,359,510.00 | 1.43 | 1.63 | 1.69 | 2.07 | 69.09 | 68.86 | 5.64 | 5.28 | 1.04 | 2.15 | 0.5059 | 164.44 | 56.93 | 13.11 | -67.28 | -- | 14.90 | 0.00 |
| Bayer AG | 5.33tn | -2.00tn | 6.61tn | 99.54k | -- | 1.68 | -- | 1.24 | -15.84 | -10.68 | 42.17 | 31.07 | 0.3404 | 1.77 | 3.90 | 415,921.60 | -12.80 | -0.9407 | -17.01 | -1.20 | 53.77 | 60.72 | -37.59 | -2.48 | 0.6725 | 7.15 | 0.5764 | -- | -4.93 | -2.12 | -751.15 | -- | -0.7993 | -4.06 |
| Chugai Pharmaceutical Co Ltd | 786.95bn | 214.73bn | 8.01tn | 7.39k | 36.54 | 8.00 | -- | 10.18 | 130.53 | 130.53 | 478.34 | 596.16 | 0.686 | 1.55 | 3.62 | -- | 18.72 | 12.76 | 22.86 | 15.21 | 65.25 | 57.63 | 27.29 | 19.27 | 2.76 | 195.73 | -- | 45.47 | 14.68 | 9.55 | 36.29 | 28.57 | 19.44 | 25.98 |
Data as of Mar 03 2021. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
16.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 29 Jan 2021 | 63.99m | 4.06% |
| The Vanguard Group, Inc.as of 31 Jan 2021 | 39.13m | 2.48% |
| Daiwa Asset Management Co. Ltd.as of 29 Jan 2021 | 29.98m | 1.90% |
| Nikko Asset Management Co., Ltd.as of 29 Jan 2021 | 29.23m | 1.85% |
| BlackRock Fund Advisorsas of 04 Feb 2021 | 25.85m | 1.64% |
| Norges Bank Investment Managementas of 31 Dec 2019 | 24.02m | 1.52% |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 04 Feb 2021 | 14.11m | 0.90% |
| T. Rowe Price International Ltd.as of 31 Dec 2020 | 10.16m | 0.65% |
| Templeton Global Advisors Ltd.as of 31 Jan 2021 | 9.23m | 0.59% |
| Baillie Gifford & Co.as of 26 Feb 2021 | 9.20m | 0.58% |
More ▼
Data from 31 Dec 2019 - 31 Dec 2020Source: FactSet Research Systems Inc.
